Literature DB >> 21497989

Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.

Sabine Mueller1, Xiaodong Yang, Theo L Sottero, Ashley Gragg, Gautam Prasad, Mei-Yin Polley, William A Weiss, Katherine K Matthay, Andrew M Davidoff, Steven G DuBois, Daphne A Haas-Kogan.   

Abstract

Histone deacetylase (HDAC) inhibitors can radiosensitize cancer cells. Radiation is critical in high-risk neuroblastoma treatment, and combinations of HDAC inhibitor vorinostat and radiation are proposed for neuroblastoma trials. Therefore, we investigated radiosensitizing effects of vorinostat in neuroblastoma. Treatment of neuroblastoma cell lines decreased cell viability and resulted in additive effects with radiation. In a murine metastatic neuroblastoma in vivo model vorinostat and radiation combinations decreased tumor volumes compared to single modality. DNA repair enzyme Ku-86 was reduced in several neuroblastoma cells treated with vorinostat. Thus, vorinostat potentiates anti-neoplastic effects of radiation in neuroblastoma possibly due to down-regulation of DNA repair enzyme Ku-86.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21497989      PMCID： PMC3244077          DOI： 10.1016/j.canlet.2011.03.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  21 in total

1.  A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response.

Authors:  Hiroshi Masumoto; David Hawke; Ryuji Kobayashi; Alain Verreault
Journal:  Nature       Date:  2005-07-14       Impact factor: 49.962

2.  Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas.

Authors:  Michal Entin-Meer; Ada Rephaeli; Xiaodong Yang; Abraham Nudelman; Scott R VandenBerg; Daphne Adele Haas-Kogan
Journal:  Mol Cancer Ther       Date:  2005-12       Impact factor: 6.261

3.  XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining.

Authors:  Peter Ahnesorg; Philippa Smith; Stephen P Jackson
Journal:  Cell       Date:  2006-01-27       Impact factor: 41.582

4.  Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

Authors:  J-H Lee; M L Choy; L Ngo; S S Foster; Paul A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

5.  Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity.

Authors:  Anupama Munshi; John F Kurland; Takashi Nishikawa; Toshimitsu Tanaka; Marvette L Hobbs; Susan L Tucker; Sheikh Ismail; Craig Stevens; Raymond E Meyn
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

6.  Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells.

Authors:  W Lutz; M Stöhr; J Schürmann; A Wenzel; A Löhr; M Schwab
Journal:  Oncogene       Date:  1996-08-15       Impact factor: 9.867

7.  Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.

Authors:  Anupama Munshi; Toshimitsu Tanaka; Marvette L Hobbs; Susan L Tucker; Victoria M Richon; Raymond E Meyn
Journal:  Mol Cancer Ther       Date:  2006-08       Impact factor: 6.261

Review 8.  Sensing and repairing DNA double-strand breaks.

Authors:  Stephen P Jackson
Journal:  Carcinogenesis       Date:  2002-05       Impact factor: 4.944

9.  Modulation of radiation response by histone deacetylase inhibition.

Authors:  Prakash Chinnaiyan; Geetha Vallabhaneni; Eric Armstrong; Shyh-Min Huang; Paul M Harari
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-05-01       Impact factor: 7.038

10.  In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas.

Authors:  Michal Entin-Meer; Xiaodong Yang; Scott R VandenBerg; Kathleen R Lamborn; Abraham Nudelman; Ada Rephaeli; Daphne Adele Haas-Kogan
Journal:  Neuro Oncol       Date:  2007-03-08       Impact factor: 12.300
View more
  33 in total

1.  Comparative effects of 4-phenyl-3-butenoic acid and vorinostat on cell growth and signaling.

Authors:  Timothy J Burns; Amna Ali; Diane F Matesic
Journal:  Anticancer Res       Date:  2015-02       Impact factor: 2.480

Review 2.  Therapeutic targets for neuroblastomas.

Authors:  Garrett M Brodeur; Radhika Iyer; Jamie L Croucher; Tiangang Zhuang; Mayumi Higashi; Venkatadri Kolla
Journal:  Expert Opin Ther Targets       Date:  2014-01-06       Impact factor: 6.902

Review 3.  Neuroblastoma.

Authors:  Andrew M Davidoff
Journal:  Semin Pediatr Surg       Date:  2012-02       Impact factor: 2.754

4.  Targeted inhibition of histone deacetylases and hedgehog signaling suppress tumor growth and homologous recombination in aerodigestive cancers.

Authors:  Stephen G Chun; Hyunsil Park; Raj K Pandita; Nobuo Horikoshi; Tej K Pandita; David L Schwartz; John S Yordy
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

Review 5.  HDAC inhibitor-based therapies: can we interpret the code?

Authors:  Maria New; Heidi Olzscha; Nicholas B La Thangue
Journal:  Mol Oncol       Date:  2012-10-23       Impact factor: 6.603

6.  Transcript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with (131)I-mIBG, a Targeted Radionuclide.

Authors:  David A Edmondson; Erin E Karski; Ayano Kohlgruber; Harsha Koneru; Katherine K Matthay; Shelly Allen; Christine L Hartmann; Leif E Peterson; Steven G DuBois; Matthew A Coleman
Journal:  Radiat Res       Date:  2016-08-24       Impact factor: 2.841

Review 7.  Epigenetic regulation of neuroblastoma development.

Authors:  Kaat Durinck; Frank Speleman
Journal:  Cell Tissue Res       Date:  2018-01-19       Impact factor: 5.249

8.  Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma.

Authors:  Sabine Mueller; Samhita Bhargava; Annette M Molinaro; Xiaodong Yang; Ilan Kolkowitz; Aleksandra Olow; Noor Wehmeijer; Sharon Orbach; Justin Chen; Katherine K Matthay; Daphne A Haas-Kogan
Journal:  Anticancer Res       Date:  2013-03       Impact factor: 2.480

9.  Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas.

Authors:  Tina Dasgupta; Daphne A Haas-Kogan; Xiaodong Yang; Aleksandra Olow; Daniel X Yang; Ashley Gragg; Lisa A Orloff; Sue S Yom
Journal:  Invest New Drugs       Date:  2013-01-26       Impact factor: 3.850

10.  Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial.

Authors:  Wenyin Shi; Yaacov Richard Lawrence; Hak Choy; Maria Werner-Wasik; David W Andrews; James J Evans; Kevin D Judy; Christopher J Farrell; Yaron Moshel; Adam C Berger; Voichita Bar-Ad; Adam P Dicker
Journal:  J Neurooncol       Date:  2014-04-13       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.